Therapeutic Solutions
International Recruits NFL Chargers Hall of Famer Wes Chandler to
Lead NeuroStilbene for Chronic Traumatic Encephalopathy in Football
Players
Company to Advance NeuroStilbene Product for
High-Performance Athletes
Susceptible to Head Injuries
Oceanside, CA --
August 22, 2018 --
InvestorsHub NewsWire -- Therapeutics
Solutions International, Inc., (OTC
Markets:
TSOI) announced today
recruitment of Wes Chandler to lead the development of its
NeuroStilbene product for use in patients at risk of
developing
chronic
traumatic encephalopathy (CTE).
Wes
Chandler was a wide
receiver in
the National
Football League (NFL)
for eleven seasons during the 1970s and 1980s. He was selected to
the Pro
Bowl four
times and ranked twelfth in NFL history in receiving yards and
thirteenth in receptions when he retired. Chandler is a member of
the San
Diego Chargers Hall of Fame. He
played college
football for
the Florida
Gators and
was also inducted into the College
Football Hall of Fame in
2015.
CTE is caused by
repetitive concussive/sub-concussive hits to the head sustained
over a period of years and is often found in football players. The
condition is characterized by memory loss, impulsive/erratic
behavior, impaired judgment, aggression, depression,
and
dementia.
In many patients with CTE, it is anatomically characterized by
brain atrophy, reduced mass of frontal and temporal
cortices, and medial temporal
lobe.
At a
molecular
level, it
is known that CTE is associated with chronic activation of a cell
type in the brain called the "microglia1". Studies have shown
that pterostilbene, the active ingredient in NeuroStilbene, is
capable of decreasing microglial activation, as well as reducing
neuroinflammation, one of the major causes of CTE2.
"I have witnessed
firsthand the devastation caused by CTE. I am very excited to work
with TSOI at developing NeuroStilbene as an over the counter spray
that is available for all athletes before exposure to activities
where the risk of brain injury/concussions exists" stated Wes
Chandler.
"We are very excited
to work with Wes and the numerous colleagues and relations he has
developed over the decades in professional sports, in order to
provide solutions that not only prevent the onset of CTE
but also
in some cases reversing
it, "said James Veltmeyer,
MD, Chief Medical Officer of the Company.
"The formal launching
of the CTE Program at TSOI is an indication of the breadth of
different therapeutic indications that the pterostilbene molecule
is capable of addressing," said Timothy Dixon, President, and CEO
of the Company. "Given that NeuroStilbene is generated from
ingredients that are Generally Regarded as Safe, the Company is
capable of initiating sales of this product immediately,
with confidence
the
market demand exists. We look forward to working with Wes and
preventing and hopefully reversing this terrible
condition.
About Therapeutic Solutions International,
Inc.
Therapeutic Solutions
International is focused on immune modulation for the treatment of
several specific diseases. Immune modulation refers to the ability
to upregulate (make more active) or downregulate (make less active)
one's immune system. The Company's corporate website is
www.therapeuticsolutionsint.com.
Blaylock et
al. Surg Neurol Int. 2011; 2: 107.
Huo et al. Prog
Neuropsychopharmacol Biol Psychiatry. 2014 Oct
3;54:92-102.
Safe Harbor
Statement
This release contains
forward-looking statements that are based upon current expectations
or beliefs, as well as a number of assumptions about future events.
Although we believe that the expectations reflected in the
forward-looking statements and the assumptions upon which they are
based are reasonable, we can give no assurance that such
expectations and assumptions will prove to have been correct.
Forward-looking statements are generally identifiable by the use of
words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. The reader is cautioned not to put undue
reliance on these forward-looking statements, as these statements
are subject to numerous risk factors as set forth in our SEC
filings. To the extent that statements in this press release are
not strictly historical, including statements as to product launch
timing, revenue projections, business strategy, outlook,
objectives, future milestones, plans, intentions, goals, future
collaboration agreements, or otherwise as to future events, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The forward-looking statements contained in this release
are subject to certain risks and uncertainties that could cause
actual results to differ materially from the statements
made.
CONTACT
INFORMATION